Changing the Normal Range for Blood Pressure from 140/90 to 130/Any Improves Risk Assessment

Similar documents
Albumin and All-Cause Mortality Risk in Insurance Applicants

Beware that Low Urine Creatinine! by Vera F. Dolan MSPH FALU, Michael Fulks MD, Robert L. Stout PhD

Urine Protein/Creatinine Ratio as a Mortality Risk Predictor in Non-Diabetics with Normal Renal Function

Using Liver Enzymes as Screening Tests to Predict Mortality Risk

Relationship of Hemoglobin A1c to Mortality in Nonsmoking Insurance Applicants

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

Main Effect of Screening for Coronary Artery Disease Using CT

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

Submitted Electronically to

Absolute cardiovascular disease risk assessment

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Product Development News

Underwriting Critical Illness Insurance: A model for coronary heart disease and stroke

Scottish Diabetes Survey

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Quantifying Life expectancy in people with Type 2 diabetes

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Social inequalities in all cause and cause specific mortality in a country of the African region

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost

How To Know If You Have Microalbuminuria

Statistical Analysis Using SPSS for Windows Getting Started (Ver. 2014/11/6) The numbers of figures in the SPSS_screenshot.pptx are shown in red.

Coronary Heart Disease (CHD) Brief

St Lucia Diabetes and Hypertension Screening and Disease Management Programs

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

Cardiovascular risk assessment: Audit findings from a nurse clinic a quality improvement initiative

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Understanding diabetes Do the recent trials help?

Isabella Sudano & Franco Muggli

ING Life Underwriting

Prognostic impact of uric acid in patients with stable coronary artery disease

Blood Pressure Assessment Program Screening Guidelines

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and

Listen to your heart: Good Cardiovascular Health for Life

How to measure blood pressure using digital monitors

Hypertension and Diabetes

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Underwriting Requirements Guide September 2014

Underwriting Requirements Guide February 2015

Trends in Part C & D Star Rating Measure Cut Points

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

PPA Educational Foundation Grant Report 2013 Kristin M. Franks

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

1990 Life Insurance and Diabetes

Achieving Quality and Value in Chronic Care Management

Pharmacy and the Medicaid Accountable Care Organization

survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Guidelines for the management of hypertension in patients with diabetes mellitus

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

Appendix: Description of the DIETRON model

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, ESRD Registry Committee, Korean Society of Nephrology*

Epidemiology of Hypertension 陈 奕 希 李 禾 园 王 卓

Cardiovascular Disease Risk Factors

METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

PREVENTIVE CARDIOLOGY CURRICULUM. Overview

Hypertension and Diabetes Status Bangladesh Demographic and Health Survey

Clinical Indicator Ages Ages Ages Ages Ages 65+ Frequency of visit as recommended by PCP

Electronic Health Record Strategies for Pay for Performance. James O Connor MD Director of Clinical Informatics

Clinical Study Synopsis for Public Disclosure

Colony Term. I Colony Term I Life Insurance. The Traditional Term Solution

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

The American Cancer Society Cancer Prevention Study I: 12-Year Followup

Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States,

on a daily basis. On the whole, however, those with heart disease are more limited in their activities, including work.

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

Does referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol

From Concept to Rapid Visualization a Data Analytics Case Study

OEM MAXNIBP Frequently Asked Questions

James F. Kravec, M.D., F.A.C.P

PRACTICE PROBLEMS FOR BIOSTATISTICS

African Americans & Cardiovascular Diseases

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

Obesity and Socioeconomic Status in Children and Adolescents: United States,

Binary Logistic Regression

Understanding Diseases and Treatments with Canadian Real-world Evidence

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

term life 10, 15, 20, 30

CDS Starter Kit: Diabetes f ollow-up care

How To Treat Dyslipidemia

Special Communication

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

MY TYPE 2 DIABETES NUMBERS

THE NHS HEALTH CHECK AND INSURANCE FREQUENTLY ASKED QUESTIONS

JACK KARDYS. DIRECTOR Miami-Dade County Parks, Recreation and Open Spaces

Human Clinical Study for Free Testosterone & Muscle Mass Boosting

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

Absolute cardiovascular disease risk management

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Blood Pressure. Blood Pressure (mm Hg) pressure exerted by blood against arterial walls. Blood Pressure. Blood Pressure

Transcription:

JOURNAL OF INSURANCE MEDICINE Copyright E 2015 Journal of Insurance Medicine J Insur Med 2015;45:28 33 MORTALITY MORTALITY Changing the Normal Range for Blood Pressure from 140/90 to 130/Any Improves Risk Assessment Michael Fulks, MD; Robert L. Stout, PhD; Vera F. Dolan, MSPH Objective. Redefine the normal reference range for blood pressure from,140/90 to one that more effectively identifies individuals with increased mortality risk. Method. Data from the recently published 2014 CRL blood pressure study was used. It includes 2,472,706 life insurance applicants tested by Clinical Reference Laboratory from 1993 to 2007 with follow-up for vital status using the September 2011 Social Security Death Master File. Various upper limits of blood pressure (BP in mm Hg) were evaluated to determine if any was superior to the current, commonly used limit of 140/90 in identifying individuals with increased mortality risk. Results. An alternative reference range using a systolic BP (SBP),130 with any diastolic BP (DBP) included 84% of life insurance applicants. It had a lower mortality rate and narrower range of relative risk than,140/90, including 89% as many applicants but only 68% as many deaths. This pattern of lives and deaths was consistent across age and sex. Conclusion. Switching to a normal reference range of SBP,130 offers superior risk assessment relative to using BP,140/90 while still including a sufficient percentage of the population. Address for Correspondence: Clinical Reference Laboratory, 454 Beltrami Drive, Ukiah, California 95482; ph: 707-463-3200; fax: 707-463-3209; dolanvp@consultancy.com Correspondent: Vera F. Dolan, MSPH. Key words: Blood pressure, hypertension, laboratory tests, life insurance, mortality. Received: July 3, 2014 Accepted: October 5, 2014 INTRODUCTION Current life insurance industry underwriting practice (and clinical practice) often lumps blood pressure (BP in mm Hg),140/90 into a single normal reference range although, for lower premium preferred classes, there will most often be further systolic BP (SBP) and/or diastolic BP (DBP) restrictions. Other cardiovascular risk measures such as lipids are usually compared to narrower, more ideal reference bands and, therefore, may play a more prominent role in underwriting decision-making on the premise that such findings are more predictive as long as the BP is,140/90. This approach may be encouraged by two recent contrasting recommendations: the Eighth Joint National Committee in 2014 suggesting that BP treatment should be limited to those with blood pressures $140/90 at younger ages and $150/90 at older ages, as compared with recent ACC/AHA guidelines on cholesterol suggesting even more widespread use of statin therapy. 1,2 Recognizing that the value of treatment does not 28

FULKS ET AL CHANGING NORMAL BP RANGE IMPROVES RISK equate to the risk, such messages may still impact risk assessment practices. In contrast, our recent BP study found SBP $130 to have substantially increased risk while higher DBP increased risk minimally. 3 In fact, low DBP with wide pulse pressure was a far more important risk determinant compared to high DBP. We therefore sought to determine if a more accurate normal reference range might be both practical and lead to better risk discrimination. METHODS Details on this pool of 2,472,706 life insurance applicants (31,033 deaths) tested between 1993 and 2007 with BP and laboratory results available are provided in our previous publication on BP. 3 All applicants with SBP between 90 and 199 and DBP between 50 and 120 were included. Followup for vital status was conducted by use of the September, 2011 Social Security Death Master File. The median duration of followup was 7 years (range 0 to 18). Relative mortality risk was calculated by Cox regression analysis using IBM SPSS version 22. The analyses were split by sex and age18to59and60to89withageandsmoking (defined as urine cotinine.200 ng/ml indicating use of tobacco or nicotine delivery device) included as covariates. Additional covariates included were age- and sex-adjusted mortality risk scores for body mass index (BMI) and for urine protein/creatinine ratio (urine p/c), and a simple positive/negative for history of heart disease. Those denying a heart disease history (66.5%) and not answering (32.6%) were combined as negative. Because BMI and urine p/c have a variable impact on relative mortality by age and sex, rather than use the values, the independent excess mortality risk (score) associated with those values (taken from previous research by the authors) was included as a covariate instead. 4-6 These additional covariates account for information which is often evaluated separately at the time of insurance underwriting or clinical assessment. RESULTS Table 1 shows the distribution of lives and deaths by age and sex using a BP reference Table 1. Distribution of Study Population by BP Reference Range, Age and Sex Blood pressure range Age-sex group Total Deaths Percent of all cases by age-sex Percent of all deaths by age-sex,130/any F 20 to 59 916,217 4,250 91.8% 77.3% F 60 to 89 44,809 2,111 65.7% 51.8% M 20 to 59 1,054,266 8,843 81.1% 64.3% M 60 to 89 63,287 3,837 59.5% 49.7% Total 2,078,579 19,041 84.1% 61.4%,140/90 F 20 to 59 972,633 5,005 97.4% 91.1% F 60 to 89 59,729 3,218 87.6% 79.0% M 20 to 59 1,223,313 11,787 94.1% 85.8% M 60 to 89 91,125 6,103 85.7% 79.0% Total 2,346,800 26,113 94.9% 84.1% All BP values F 20 to 59 998,113 5,495 F 60 to 89 68,187 4,073 M 20 to 59 1,300,053 13,744 M 60 to 89 106,353 7,721 Total 2,472,706 31,033 29

JOURNAL OF INSURANCE MEDICINE Table 2. Relative Mortality by BP for Four Age-Sex Groups Using BP,140/90 as the Reference Range Systolic BP Female age 18-59 Male age 18-59 Female age 60-89 Male age 60-89 90-139 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 89 (ref) 1.00 1.00 1.00 1.00 130-139 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 90 to 120 1.38 1.05 1.81 1.41 1.24 1.59 1.50 1.07 2.11 0.97 0.75 1.25 140-149 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 69 2.55 1.14 5.67 2.41 1.59 3.67 1.75 1.34 2.30 1.46 1.13 1.88 70 to 79 1.46 1.00 2.13 1.40 1.14 1.71 1.29 1.07 1.55 1.17 1.02 1.34 80 to 89 1.38 1.14 1.68 1.46 1.32 1.60 1.18 1.02 1.37 1.18 1.07 1.30 90 to 120 1.53 1.20 1.95 1.47 1.31 1.64 1.34 1.02 1.76 1.16 0.97 1.38 150-159 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 69 n/a n/a n/a n/a n/a n/a 1.27 0.72 2.24 1.49 0.94 2.37 70 to 79 2.35 1.17 4.70 2.80 1.95 4.00 1.56 1.18 2.07 1.38 1.10 1.74 80 to 89 2.17 1.57 2.99 1.93 1.61 2.32 1.28 1.01 1.61 1.23 1.05 1.45 90 to 120 1.52 1.11 2.08 1.76 1.52 2.04 1.69 1.27 2.24 1.34 1.11 1.63 160-199 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 69 n/a n/a n/a n/a n/a n/a 1.31 0.62 2.74 2.65 1.69 4.16 70 to 79 3.03 1.36 6.75 1.82 0.98 3.38 1.93 1.36 2.74 1.12 0.79 1.58 80 to 89 2.23 1.40 3.56 2.05 1.55 2.71 1.44 1.11 1.86 1.25 1.01 1.54 90 to 120 2.41 1.86 3.12 2.17 1.88 2.50 1.52 1.17 1.97 1.33 1.11 1.59 n/a 5 Number of deaths,5 30

FULKS ET AL CHANGING NORMAL BP RANGE IMPROVES RISK Table 3. Relative Mortality by BP for Four Age-Sex Groups Using BP,130/Any as the Reference Range Systolic BP Female age 18-59 Male age 18-59 Female age 60-89 Male age 60-89 90-129 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 120 (ref) 1.00 1.00 1.00 1.00 130-139 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 59 n/a n/a n/a n/a n/a n/a 1.35 0.70 2.59 2.18 1.39 3.42 60 to 69 2.10 1.52 2.89 1.71 1.40 2.09 1.51 1.27 1.80 1.37 1.19 1.57 70 to 79 1.28 1.11 1.48 1.30 1.21 1.41 1.28 1.15 1.43 1.17 1.09 1.27 80 to 89 1.33 1.20 1.47 1.37 1.31 1.44 1.26 1.14 1.39 1.12 1.05 1.20 90 to 120 1.45 1.10 1.91 1.52 1.34 1.71 1.63 1.16 2.29 1.02 0.80 1.32 140-149 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 69 2.69 1.21 5.99 2.63 1.73 3.99 1.92 1.46 2.53 1.55 1.20 2.00 70 to 79 1.55 1.06 2.26 1.52 1.24 1.86 1.41 1.17 1.70 1.24 1.07 1.42 80 to 89 1.47 1.21 1.78 1.58 1.44 1.75 1.29 1.11 1.50 1.24 1.12 1.37 90 to 120 1.62 1.27 2.06 1.59 1.42 1.78 1.46 1.11 1.91 1.22 1.03 1.46 150-159 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 69 n/a n/a n/a n/a n/a n/a 1.40 0.79 2.47 1.58 1.00 2.52 70 to 79 2.50 1.25 5.01 3.05 2.13 4.36 1.71 1.29 2.27 1.47 1.16 1.85 80 to 89 2.31 1.67 3.18 2.11 1.76 2.54 1.40 1.11 1.76 1.30 1.11 1.54 90 to 120 1.62 1.19 2.22 1.92 1.66 2.22 1.84 1.39 2.44 1.42 1.17 1.73 160-199 MR 95% CI MR 95% CI MR 95% CI MR 95% CI 50 to 69 n/a n/a n/a n/a n/a n/a 1.44 0.68 3.02 2.82 1.79 4.42 70 to 79 3.24 1.45 7.21 1.99 1.07 3.70 2.11 1.49 3.00 1.19 0.84 1.68 80 to 89 2.39 1.50 3.81 2.25 1.70 2.98 1.57 1.21 2.03 1.33 1.07 1.64 90 to 120 2.58 1.99 3.33 2.38 2.06 2.74 1.65 1.27 2.15 1.40 1.17 1.68 n/a 5 Number of deaths,5 31

JOURNAL OF INSURANCE MEDICINE range of,140/90 and the alternative of,130/any. We found that 84.1% of applicants had SBP,130 with no diastolic restrictions and 94.9% had BP,140/90. For males age 60+ (group with the highest average BP), those percentages were 59.5% and 85.7% respectively. In contrast, the percentage of deaths included in BP,130 for all age-sex was only 61.4% compared to 84.1% for BP,140/90. Table 1 also shows that this pattern of a lower percentage of deaths included using 130/any is consistent across the age-sex groups rather than simply a shift to younger lives. Overall, using an SBP of,130 as a cut-off relative to using BP,140/90 included 88.6% as many lives and 72.9% as many deaths. Table 2 displays the relative mortality using a reference range of,140/90 and Table 3 shows the same information for a reference range of,130/any. These mortality ratios have been adjusted for age, cotinine status, BMI risk, urine p/c risk, and admitted history of heart disease. Using BP,130/any reveals the excess risk associated with the very common finding of SBP 130 to 139, where relative mortality is increased by approximately 30%, except for males age 60+ where the increase is less. A higher relative risk is also seen using,130/ any rather than,140/90 for the less common SBP $140. Both Tables 2 and 3 illustrate that within each SBP band, risk associated with progressively higher DBP changes little. DISCUSSION In contrast to many diseases, hypertension (by any definition) is common so that the healthy reference pool is relatively smaller. It is also associated with increased mortality risk beginning at SBP well below 140 while DBP adds little risk discrimination (to SBP) as it increases from average to high levels. 3 This led us on a hunt for a better normal reference band that offered superior identification of increased risk associated with elevated BP while remaining large enough to be practical for screening purposes. In our prior paper, when comparing SBP 90-119 (lowest relative risk) to SBP 125-129, relative mortality increased by 13% to 32% depending on age and sex, a range of risk we felt was probably acceptable within a normal pool. However, SBP $130 expanded this risk range, substantially increasing risk by roughly 30% for each 10 mm Hg. Using BP,130/any still includes 84.1% of applicants. Reaching the 94.9% included in BP,140/90 using SBP only would require a cut-off of,138/any. Both,140/90 and,138/any include substantial BP-associated excess mortality relative to using,130/any. The percentage of applicants included in,130/any when split by age and sex (older males being the lowest) relative to risk discrimination achieved also appears both satisfactory and superior to using BP,140/90. The risk associated with DBP within each SBP band is highest with the lowest DBP rather than increasing as DBP increases. This is discussed in our earlier paper with pulse pressure/sbp.k (1% of applicants) identifying the excess risk associated with low DBP. Limitations for our study include dependence on 1 to 3 BP measurements (just one for 24% of applicants) done at a single exam. In addition, our heart disease history was obtained from a question on the laboratory authorization (answer encouraged but usually not required) rather than on the insurance application. Our population of individual life insurance applicants also has fewer serious medical conditions and higher socio-economic status as compared to a general population sample. CONCLUSION Rather than use the pool of those with BP,140/90 as a reference to identify insurance applicants or those at a wellness exam as having increased risk, limiting that pool to those with SBP,130 without a cut-off for high DBP offers better risk assessment. 32

FULKS ET AL CHANGING NORMAL BP RANGE IMPROVES RISK REFERENCES 1. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure. Report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA. 2014;311:507 520. 2. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2013. online: http:// circ.ahajournals.org/content/early/2013/11/11/ 01.cir.0000437738.63853.7a.citation 3. Fulks M, Stout RL, Dolan VF. 2014 CRL BP study. J Insur Med. 2015;45:17 27. 4. Fulks M, Stout RL, Dolan VF. Scoring life insurance applicants laboratory results, blood pressure and build to predict all-cause mortality risk. J Insur Med. 2012;43:169 177. 5. Fulks M, Stout RL, Dolan VF. 2014 CRL build study. J Ins Med. In press. 6. Fulks M, Stout RL, Dolan VF. Urine protein/ creatinine ratio as a mortality risk predictor in non-diabetics with normal renal function. J Insur Med. 2012;43:76 83. 33